IOVANCE BIOTHERAPEUTICS: Board Changes & Executive Compensation Updates

Ticker: IOVA · Form: 8-K · Filed: Jul 3, 2025 · CIK: 1425205

Iovance Biotherapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyIovance Biotherapeutics, Inc. (IOVA)
Form Type8-K
Filed DateJul 3, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: management-change, executive-compensation, board-of-directors

Related Tickers: IOVA

TL;DR

IOVA board shakeup: new directors Pizzo & VanLent in, CEO Vogt & CMO Daniel get new employment deals.

AI Summary

On June 30, 2025, IOVANCE BIOTHERAPEUTICS, INC. announced changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Philip A. Pizzo and Ms. Anne M. VanLent, to its Board of Directors, effective immediately. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Dr. Frederick Vogt, and Chief Medical Officer, Dr. Elias K. Daniel, detailing their compensation and terms of employment.

Why It Matters

These changes in board composition and executive compensation can signal shifts in company strategy, governance, and management's commitment, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts or strategic realignments that may carry inherent risks.

Key Players & Entities

  • IOVANCE BIOTHERAPEUTICS, INC. (company) — Registrant
  • Dr. Philip A. Pizzo (person) — Newly Elected Director
  • Ms. Anne M. VanLent (person) — Newly Elected Director
  • Dr. Frederick Vogt (person) — Chief Executive Officer
  • Dr. Elias K. Daniel (person) — Chief Medical Officer
  • June 30, 2025 (date) — Effective date of board changes and employment agreements

FAQ

Who were the new directors elected to IOVANCE BIOTHERAPEUTICS, INC.'s Board of Directors?

Dr. Philip A. Pizzo and Ms. Anne M. VanLent were elected as new directors, effective June 30, 2025.

What is the effective date of the reported changes?

The earliest event reported is dated June 30, 2025.

Which executive officers entered into new employment agreements?

Dr. Frederick Vogt, the Chief Executive Officer, and Dr. Elias K. Daniel, the Chief Medical Officer, entered into new employment agreements.

What is the state of incorporation for IOVANCE BIOTHERAPEUTICS, INC.?

The company is incorporated in Delaware.

What is the Commission File Number for IOVANCE BIOTHERAPEUTICS, INC.?

The Commission File Number is 001-36860.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 3, 2025 by Dr. Philip A. Pizzo regarding IOVANCE BIOTHERAPEUTICS, INC. (IOVA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.